Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer Article Swipe
Tal Flieswasser
,
Astrid Van den Eynde
,
Laurie Freire Boullosa
,
Jöran Melis
,
Christophe Hermans
,
Céline Merlin
,
Ho Wa Lau
,
Jonas Van Audenaerde
,
Filip Lardon
,
Evelien Smits
,
Patrick Pauwels
,
Julie Jacobs
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1080/2162402x.2023.2192100
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1080/2162402x.2023.2192100
Despite the recent emergence of immune checkpoint inhibitors, clinical outcomes of metastatic NSCLC patients remain poor, pointing out the unmet need to develop novel therapies to enhance the anti-tumor immune response in NSCLC. In this regard, aberrant expression of the immune checkpoint molecule CD70 has been reported on many cancer types, including NSCLC. In this study, the cytotoxic and immune stimulatory potential of an antibody-based anti-CD70 (aCD70) therapy was explored as single agent and in combination with docetaxel and cisplatin in NSCLC in vitro and in vivo. Anti-CD70 therapy resulted in NK-mediated killing of NSCLC cells and increased production of pro-inflammatory cytokines by NK cells in vitro. The combination of chemotherapy and anti-CD70 therapy further enhanced NSCLC cell killing. Moreover, in vivo findings showed that the sequential treatment of chemo-immunotherapy resulted in a significant improved survival and delayed tumor growth compared to single agents in Lewis Lung carcinoma-bearing mice. The immunogenic potential of the chemotherapeutic regimen was further highlighted by increased numbers of dendritic cells in the tumor-draining lymph nodes in these tumor-bearing mice after treatment. The sequential combination therapy resulted in enhanced intratumoral infiltration of both T and NK cells, as well as an increase in the ratio of CD8+ T cells over Tregs. The superior effect of the sequential combination therapy on survival was further confirmed in a NCI-H1975-bearing humanized IL15-NSG-CD34+ mouse model. These novel preclinical data demonstrate the potential of combining chemotherapy and aCD70 therapy to enhance anti-tumor immune responses in NSCLC patients.
Related Topics
Concepts
Cancer research
Lewis lung carcinoma
Immune system
Combination therapy
Immunotherapy
Medicine
Lung cancer
Docetaxel
Cytotoxic T cell
CD8
Immune checkpoint
In vivo
Immunology
Chemotherapy
Cancer
Oncology
Pharmacology
Internal medicine
In vitro
Biology
Metastasis
Biotechnology
Biochemistry
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1080/2162402x.2023.2192100
- OA Status
- gold
- Cited By
- 10
- References
- 35
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4360615710
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4360615710Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1080/2162402x.2023.2192100Digital Object Identifier
- Title
-
Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancerWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-03-23Full publication date if available
- Authors
-
Tal Flieswasser, Astrid Van den Eynde, Laurie Freire Boullosa, Jöran Melis, Christophe Hermans, Céline Merlin, Ho Wa Lau, Jonas Van Audenaerde, Filip Lardon, Evelien Smits, Patrick Pauwels, Julie JacobsList of authors in order
- Landing page
-
https://doi.org/10.1080/2162402x.2023.2192100Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1080/2162402x.2023.2192100Direct OA link when available
- Concepts
-
Cancer research, Lewis lung carcinoma, Immune system, Combination therapy, Immunotherapy, Medicine, Lung cancer, Docetaxel, Cytotoxic T cell, CD8, Immune checkpoint, In vivo, Immunology, Chemotherapy, Cancer, Oncology, Pharmacology, Internal medicine, In vitro, Biology, Metastasis, Biotechnology, BiochemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
10Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 3, 2024: 5, 2023: 2Per-year citation counts (last 5 years)
- References (count)
-
35Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4360615710 |
|---|---|
| doi | https://doi.org/10.1080/2162402x.2023.2192100 |
| ids.doi | https://doi.org/10.1080/2162402x.2023.2192100 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/36970072 |
| ids.openalex | https://openalex.org/W4360615710 |
| fwci | 2.37597027 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000818 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Animals |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D051379 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Mice |
| mesh[2].qualifier_ui | Q000188 |
| mesh[2].descriptor_ui | D002289 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | drug therapy |
| mesh[2].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[3].qualifier_ui | Q000473 |
| mesh[3].descriptor_ui | D002289 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | pathology |
| mesh[3].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[4].qualifier_ui | Q000188 |
| mesh[4].descriptor_ui | D008175 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | drug therapy |
| mesh[4].descriptor_name | Lung Neoplasms |
| mesh[5].qualifier_ui | Q000473 |
| mesh[5].descriptor_ui | D008175 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | pathology |
| mesh[5].descriptor_name | Lung Neoplasms |
| mesh[6].qualifier_ui | Q000494 |
| mesh[6].descriptor_ui | D000970 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | pharmacology |
| mesh[6].descriptor_name | Antineoplastic Agents |
| mesh[7].qualifier_ui | Q000627 |
| mesh[7].descriptor_ui | D000970 |
| mesh[7].is_major_topic | True |
| mesh[7].qualifier_name | therapeutic use |
| mesh[7].descriptor_name | Antineoplastic Agents |
| mesh[8].qualifier_ui | Q000494 |
| mesh[8].descriptor_ui | D000077143 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | pharmacology |
| mesh[8].descriptor_name | Docetaxel |
| mesh[9].qualifier_ui | Q000627 |
| mesh[9].descriptor_ui | D000077143 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | therapeutic use |
| mesh[9].descriptor_name | Docetaxel |
| mesh[10].qualifier_ui | Q000494 |
| mesh[10].descriptor_ui | D002945 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | pharmacology |
| mesh[10].descriptor_name | Cisplatin |
| mesh[11].qualifier_ui | Q000627 |
| mesh[11].descriptor_ui | D002945 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | therapeutic use |
| mesh[11].descriptor_name | Cisplatin |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D000818 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Animals |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D051379 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Mice |
| mesh[14].qualifier_ui | Q000188 |
| mesh[14].descriptor_ui | D002289 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | drug therapy |
| mesh[14].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[15].qualifier_ui | Q000473 |
| mesh[15].descriptor_ui | D002289 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | pathology |
| mesh[15].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[16].qualifier_ui | Q000188 |
| mesh[16].descriptor_ui | D008175 |
| mesh[16].is_major_topic | True |
| mesh[16].qualifier_name | drug therapy |
| mesh[16].descriptor_name | Lung Neoplasms |
| mesh[17].qualifier_ui | Q000473 |
| mesh[17].descriptor_ui | D008175 |
| mesh[17].is_major_topic | True |
| mesh[17].qualifier_name | pathology |
| mesh[17].descriptor_name | Lung Neoplasms |
| mesh[18].qualifier_ui | Q000494 |
| mesh[18].descriptor_ui | D000970 |
| mesh[18].is_major_topic | True |
| mesh[18].qualifier_name | pharmacology |
| mesh[18].descriptor_name | Antineoplastic Agents |
| mesh[19].qualifier_ui | Q000627 |
| mesh[19].descriptor_ui | D000970 |
| mesh[19].is_major_topic | True |
| mesh[19].qualifier_name | therapeutic use |
| mesh[19].descriptor_name | Antineoplastic Agents |
| mesh[20].qualifier_ui | Q000494 |
| mesh[20].descriptor_ui | D000077143 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | pharmacology |
| mesh[20].descriptor_name | Docetaxel |
| mesh[21].qualifier_ui | Q000627 |
| mesh[21].descriptor_ui | D000077143 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | therapeutic use |
| mesh[21].descriptor_name | Docetaxel |
| mesh[22].qualifier_ui | Q000494 |
| mesh[22].descriptor_ui | D002945 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | pharmacology |
| mesh[22].descriptor_name | Cisplatin |
| mesh[23].qualifier_ui | Q000627 |
| mesh[23].descriptor_ui | D002945 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | therapeutic use |
| mesh[23].descriptor_name | Cisplatin |
| type | article |
| title | Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer |
| biblio.issue | 1 |
| biblio.volume | 12 |
| biblio.last_page | 2192100 |
| biblio.first_page | 2192100 |
| grants[0].funder | https://openalex.org/F4320327317 |
| grants[0].award_id | |
| grants[0].funder_display_name | Kom op tegen Kanker |
| topics[0].id | https://openalex.org/T10158 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | Cancer Immunotherapy and Biomarkers |
| topics[1].id | https://openalex.org/T10580 |
| topics[1].field.id | https://openalex.org/fields/24 |
| topics[1].field.display_name | Immunology and Microbiology |
| topics[1].score | 0.9991000294685364 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2403 |
| topics[1].subfield.display_name | Immunology |
| topics[1].display_name | Immunotherapy and Immune Responses |
| topics[2].id | https://openalex.org/T12334 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9980000257492065 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | Lung Cancer Research Studies |
| funders[0].id | https://openalex.org/F4320327317 |
| funders[0].ror | |
| funders[0].display_name | Kom op tegen Kanker |
| is_xpac | False |
| apc_list.value | 2375 |
| apc_list.currency | GBP |
| apc_list.value_usd | 2913 |
| apc_paid.value | 2375 |
| apc_paid.currency | GBP |
| apc_paid.value_usd | 2913 |
| concepts[0].id | https://openalex.org/C502942594 |
| concepts[0].level | 1 |
| concepts[0].score | 0.5885118246078491 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[0].display_name | Cancer research |
| concepts[1].id | https://openalex.org/C2777847059 |
| concepts[1].level | 4 |
| concepts[1].score | 0.5856291055679321 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q6537255 |
| concepts[1].display_name | Lewis lung carcinoma |
| concepts[2].id | https://openalex.org/C8891405 |
| concepts[2].level | 2 |
| concepts[2].score | 0.575146496295929 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q1059 |
| concepts[2].display_name | Immune system |
| concepts[3].id | https://openalex.org/C2776999253 |
| concepts[3].level | 2 |
| concepts[3].score | 0.5572397112846375 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q1304270 |
| concepts[3].display_name | Combination therapy |
| concepts[4].id | https://openalex.org/C2777701055 |
| concepts[4].level | 3 |
| concepts[4].score | 0.5547625422477722 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[4].display_name | Immunotherapy |
| concepts[5].id | https://openalex.org/C71924100 |
| concepts[5].level | 0 |
| concepts[5].score | 0.5518496632575989 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[5].display_name | Medicine |
| concepts[6].id | https://openalex.org/C2776256026 |
| concepts[6].level | 2 |
| concepts[6].score | 0.5463545322418213 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q47912 |
| concepts[6].display_name | Lung cancer |
| concepts[7].id | https://openalex.org/C2781190966 |
| concepts[7].level | 3 |
| concepts[7].score | 0.5006146430969238 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q420436 |
| concepts[7].display_name | Docetaxel |
| concepts[8].id | https://openalex.org/C154317977 |
| concepts[8].level | 3 |
| concepts[8].score | 0.46998894214630127 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q376266 |
| concepts[8].display_name | Cytotoxic T cell |
| concepts[9].id | https://openalex.org/C167672396 |
| concepts[9].level | 3 |
| concepts[9].score | 0.4652579426765442 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q417800 |
| concepts[9].display_name | CD8 |
| concepts[10].id | https://openalex.org/C2780851360 |
| concepts[10].level | 4 |
| concepts[10].score | 0.4327487349510193 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q21686041 |
| concepts[10].display_name | Immune checkpoint |
| concepts[11].id | https://openalex.org/C207001950 |
| concepts[11].level | 2 |
| concepts[11].score | 0.4187732934951782 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q141124 |
| concepts[11].display_name | In vivo |
| concepts[12].id | https://openalex.org/C203014093 |
| concepts[12].level | 1 |
| concepts[12].score | 0.41202616691589355 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[12].display_name | Immunology |
| concepts[13].id | https://openalex.org/C2776694085 |
| concepts[13].level | 2 |
| concepts[13].score | 0.3878313899040222 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[13].display_name | Chemotherapy |
| concepts[14].id | https://openalex.org/C121608353 |
| concepts[14].level | 2 |
| concepts[14].score | 0.34194421768188477 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[14].display_name | Cancer |
| concepts[15].id | https://openalex.org/C143998085 |
| concepts[15].level | 1 |
| concepts[15].score | 0.2757062017917633 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[15].display_name | Oncology |
| concepts[16].id | https://openalex.org/C98274493 |
| concepts[16].level | 1 |
| concepts[16].score | 0.24221616983413696 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[16].display_name | Pharmacology |
| concepts[17].id | https://openalex.org/C126322002 |
| concepts[17].level | 1 |
| concepts[17].score | 0.22852233052253723 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[17].display_name | Internal medicine |
| concepts[18].id | https://openalex.org/C202751555 |
| concepts[18].level | 2 |
| concepts[18].score | 0.21915611624717712 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q221681 |
| concepts[18].display_name | In vitro |
| concepts[19].id | https://openalex.org/C86803240 |
| concepts[19].level | 0 |
| concepts[19].score | 0.2060498297214508 |
| concepts[19].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[19].display_name | Biology |
| concepts[20].id | https://openalex.org/C2779013556 |
| concepts[20].level | 3 |
| concepts[20].score | 0.12392163276672363 |
| concepts[20].wikidata | https://www.wikidata.org/wiki/Q181876 |
| concepts[20].display_name | Metastasis |
| concepts[21].id | https://openalex.org/C150903083 |
| concepts[21].level | 1 |
| concepts[21].score | 0.0 |
| concepts[21].wikidata | https://www.wikidata.org/wiki/Q7108 |
| concepts[21].display_name | Biotechnology |
| concepts[22].id | https://openalex.org/C55493867 |
| concepts[22].level | 1 |
| concepts[22].score | 0.0 |
| concepts[22].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[22].display_name | Biochemistry |
| keywords[0].id | https://openalex.org/keywords/cancer-research |
| keywords[0].score | 0.5885118246078491 |
| keywords[0].display_name | Cancer research |
| keywords[1].id | https://openalex.org/keywords/lewis-lung-carcinoma |
| keywords[1].score | 0.5856291055679321 |
| keywords[1].display_name | Lewis lung carcinoma |
| keywords[2].id | https://openalex.org/keywords/immune-system |
| keywords[2].score | 0.575146496295929 |
| keywords[2].display_name | Immune system |
| keywords[3].id | https://openalex.org/keywords/combination-therapy |
| keywords[3].score | 0.5572397112846375 |
| keywords[3].display_name | Combination therapy |
| keywords[4].id | https://openalex.org/keywords/immunotherapy |
| keywords[4].score | 0.5547625422477722 |
| keywords[4].display_name | Immunotherapy |
| keywords[5].id | https://openalex.org/keywords/medicine |
| keywords[5].score | 0.5518496632575989 |
| keywords[5].display_name | Medicine |
| keywords[6].id | https://openalex.org/keywords/lung-cancer |
| keywords[6].score | 0.5463545322418213 |
| keywords[6].display_name | Lung cancer |
| keywords[7].id | https://openalex.org/keywords/docetaxel |
| keywords[7].score | 0.5006146430969238 |
| keywords[7].display_name | Docetaxel |
| keywords[8].id | https://openalex.org/keywords/cytotoxic-t-cell |
| keywords[8].score | 0.46998894214630127 |
| keywords[8].display_name | Cytotoxic T cell |
| keywords[9].id | https://openalex.org/keywords/cd8 |
| keywords[9].score | 0.4652579426765442 |
| keywords[9].display_name | CD8 |
| keywords[10].id | https://openalex.org/keywords/immune-checkpoint |
| keywords[10].score | 0.4327487349510193 |
| keywords[10].display_name | Immune checkpoint |
| keywords[11].id | https://openalex.org/keywords/in-vivo |
| keywords[11].score | 0.4187732934951782 |
| keywords[11].display_name | In vivo |
| keywords[12].id | https://openalex.org/keywords/immunology |
| keywords[12].score | 0.41202616691589355 |
| keywords[12].display_name | Immunology |
| keywords[13].id | https://openalex.org/keywords/chemotherapy |
| keywords[13].score | 0.3878313899040222 |
| keywords[13].display_name | Chemotherapy |
| keywords[14].id | https://openalex.org/keywords/cancer |
| keywords[14].score | 0.34194421768188477 |
| keywords[14].display_name | Cancer |
| keywords[15].id | https://openalex.org/keywords/oncology |
| keywords[15].score | 0.2757062017917633 |
| keywords[15].display_name | Oncology |
| keywords[16].id | https://openalex.org/keywords/pharmacology |
| keywords[16].score | 0.24221616983413696 |
| keywords[16].display_name | Pharmacology |
| keywords[17].id | https://openalex.org/keywords/internal-medicine |
| keywords[17].score | 0.22852233052253723 |
| keywords[17].display_name | Internal medicine |
| keywords[18].id | https://openalex.org/keywords/in-vitro |
| keywords[18].score | 0.21915611624717712 |
| keywords[18].display_name | In vitro |
| keywords[19].id | https://openalex.org/keywords/biology |
| keywords[19].score | 0.2060498297214508 |
| keywords[19].display_name | Biology |
| keywords[20].id | https://openalex.org/keywords/metastasis |
| keywords[20].score | 0.12392163276672363 |
| keywords[20].display_name | Metastasis |
| language | en |
| locations[0].id | doi:10.1080/2162402x.2023.2192100 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2497914550 |
| locations[0].source.issn | 2162-4011, 2162-402X |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2162-4011 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | OncoImmunology |
| locations[0].source.host_organization | https://openalex.org/P4310315740 |
| locations[0].source.host_organization_name | Landes Bioscience |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310315740 |
| locations[0].license | cc-by-nc |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | OncoImmunology |
| locations[0].landing_page_url | https://doi.org/10.1080/2162402x.2023.2192100 |
| locations[1].id | pmid:36970072 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Oncoimmunology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/36970072 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:10038060 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | cc-by-nc |
| locations[2].pdf_url | https://pmc.ncbi.nlm.nih.gov/articles/PMC10038060/pdf/KONI_12_2192100.pdf |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/cc-by-nc |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Oncoimmunology |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/10038060 |
| locations[3].id | pmh:c:irua:196025 |
| locations[3].is_oa | False |
| locations[3].source.id | https://openalex.org/S4306401849 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | Institutional Repository University of Antwerp (University of Antwerp) |
| locations[3].source.host_organization | https://openalex.org/I149213910 |
| locations[3].source.host_organization_name | University of Antwerp |
| locations[3].source.host_organization_lineage | https://openalex.org/I149213910 |
| locations[3].license | |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | |
| locations[3].license_id | |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | |
| locations[3].landing_page_url | https://hdl.handle.net/10067/1960250151162165141 |
| locations[4].id | pmh:oai:doaj.org/article:917fde71ee3a406dbdd2c8728bea3a41 |
| locations[4].is_oa | False |
| locations[4].source.id | https://openalex.org/S4306401280 |
| locations[4].source.issn | |
| locations[4].source.type | repository |
| locations[4].source.is_oa | False |
| locations[4].source.issn_l | |
| locations[4].source.is_core | False |
| locations[4].source.is_in_doaj | False |
| locations[4].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[4].source.host_organization | |
| locations[4].source.host_organization_name | |
| locations[4].source.host_organization_lineage | |
| locations[4].license | |
| locations[4].pdf_url | |
| locations[4].version | submittedVersion |
| locations[4].raw_type | article |
| locations[4].license_id | |
| locations[4].is_accepted | False |
| locations[4].is_published | False |
| locations[4].raw_source_name | OncoImmunology, Vol 12, Iss 1 (2023) |
| locations[4].landing_page_url | https://doaj.org/article/917fde71ee3a406dbdd2c8728bea3a41 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5079224330 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-6348-3204 |
| authorships[0].author.display_name | Tal Flieswasser |
| authorships[0].countries | BE |
| authorships[0].affiliations[0].raw_affiliation_string | Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium |
| authorships[0].affiliations[1].institution_ids | https://openalex.org/I4210102047 |
| authorships[0].affiliations[1].raw_affiliation_string | Department of Pathology, Antwerp University Hospital, Edegem, Belgium |
| authorships[0].institutions[0].id | https://openalex.org/I4210102047 |
| authorships[0].institutions[0].ror | https://ror.org/01hwamj44 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210102047 |
| authorships[0].institutions[0].country_code | BE |
| authorships[0].institutions[0].display_name | Antwerp University Hospital |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Tal Flieswasser |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium, Department of Pathology, Antwerp University Hospital, Edegem, Belgium |
| authorships[1].author.id | https://openalex.org/A5010506461 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Astrid Van den Eynde |
| authorships[1].countries | BE |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210102047 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Pathology, Antwerp University Hospital, Edegem, Belgium |
| authorships[1].affiliations[1].raw_affiliation_string | Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium |
| authorships[1].institutions[0].id | https://openalex.org/I4210102047 |
| authorships[1].institutions[0].ror | https://ror.org/01hwamj44 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210102047 |
| authorships[1].institutions[0].country_code | BE |
| authorships[1].institutions[0].display_name | Antwerp University Hospital |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Astrid Van den Eynde |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium, Department of Pathology, Antwerp University Hospital, Edegem, Belgium |
| authorships[2].author.id | https://openalex.org/A5069190230 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-6788-6211 |
| authorships[2].author.display_name | Laurie Freire Boullosa |
| authorships[2].affiliations[0].raw_affiliation_string | Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Laurie Freire Boullosa |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium |
| authorships[3].author.id | https://openalex.org/A5066994755 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-0776-7936 |
| authorships[3].author.display_name | Jöran Melis |
| authorships[3].affiliations[0].raw_affiliation_string | Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Jöran Melis |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium |
| authorships[4].author.id | https://openalex.org/A5039751292 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Christophe Hermans |
| authorships[4].affiliations[0].raw_affiliation_string | Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Christophe Hermans |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium |
| authorships[5].author.id | https://openalex.org/A5013881555 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Céline Merlin |
| authorships[5].affiliations[0].raw_affiliation_string | Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Céline Merlin |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium |
| authorships[6].author.id | https://openalex.org/A5057833376 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Ho Wa Lau |
| authorships[6].affiliations[0].raw_affiliation_string | Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Ho Wa Lau |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium |
| authorships[7].author.id | https://openalex.org/A5026684098 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-5619-1913 |
| authorships[7].author.display_name | Jonas Van Audenaerde |
| authorships[7].affiliations[0].raw_affiliation_string | Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Jonas Van Audenaerde |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium |
| authorships[8].author.id | https://openalex.org/A5007235093 |
| authorships[8].author.orcid | https://orcid.org/0000-0001-7174-4144 |
| authorships[8].author.display_name | Filip Lardon |
| authorships[8].affiliations[0].raw_affiliation_string | Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Filip Lardon |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium |
| authorships[9].author.id | https://openalex.org/A5069580321 |
| authorships[9].author.orcid | https://orcid.org/0000-0001-9255-3435 |
| authorships[9].author.display_name | Evelien Smits |
| authorships[9].countries | BE |
| authorships[9].affiliations[0].raw_affiliation_string | Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium |
| authorships[9].affiliations[1].institution_ids | https://openalex.org/I4210102047 |
| authorships[9].affiliations[1].raw_affiliation_string | Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium |
| authorships[9].institutions[0].id | https://openalex.org/I4210102047 |
| authorships[9].institutions[0].ror | https://ror.org/01hwamj44 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210102047 |
| authorships[9].institutions[0].country_code | BE |
| authorships[9].institutions[0].display_name | Antwerp University Hospital |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Evelien Smits |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium, Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium |
| authorships[10].author.id | https://openalex.org/A5056727791 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-8553-1921 |
| authorships[10].author.display_name | Patrick Pauwels |
| authorships[10].countries | BE |
| authorships[10].affiliations[0].raw_affiliation_string | Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium |
| authorships[10].affiliations[1].institution_ids | https://openalex.org/I4210102047 |
| authorships[10].affiliations[1].raw_affiliation_string | Department of Pathology, Antwerp University Hospital, Edegem, Belgium |
| authorships[10].institutions[0].id | https://openalex.org/I4210102047 |
| authorships[10].institutions[0].ror | https://ror.org/01hwamj44 |
| authorships[10].institutions[0].type | healthcare |
| authorships[10].institutions[0].lineage | https://openalex.org/I4210102047 |
| authorships[10].institutions[0].country_code | BE |
| authorships[10].institutions[0].display_name | Antwerp University Hospital |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Patrick Pauwels |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium, Department of Pathology, Antwerp University Hospital, Edegem, Belgium |
| authorships[11].author.id | https://openalex.org/A5017717631 |
| authorships[11].author.orcid | https://orcid.org/0000-0003-2873-3364 |
| authorships[11].author.display_name | Julie Jacobs |
| authorships[11].countries | BE |
| authorships[11].affiliations[0].raw_affiliation_string | Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium |
| authorships[11].affiliations[1].institution_ids | https://openalex.org/I124674891, https://openalex.org/I4210157284 |
| authorships[11].affiliations[1].raw_affiliation_string | Argenx BV, Zwijnaarde, Belgium |
| authorships[11].institutions[0].id | https://openalex.org/I124674891 |
| authorships[11].institutions[0].ror | https://ror.org/05s030550 |
| authorships[11].institutions[0].type | company |
| authorships[11].institutions[0].lineage | https://openalex.org/I124674891 |
| authorships[11].institutions[0].country_code | BE |
| authorships[11].institutions[0].display_name | Ablynx (Belgium) |
| authorships[11].institutions[1].id | https://openalex.org/I4210157284 |
| authorships[11].institutions[1].ror | https://ror.org/04spfxf63 |
| authorships[11].institutions[1].type | company |
| authorships[11].institutions[1].lineage | https://openalex.org/I4210157284 |
| authorships[11].institutions[1].country_code | BE |
| authorships[11].institutions[1].display_name | Argenx (Belgium) |
| authorships[11].author_position | last |
| authorships[11].raw_author_name | Julie Jacobs |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Argenx BV, Zwijnaarde, Belgium, Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Wilrijk, Belgium |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1080/2162402x.2023.2192100 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10158 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | Cancer Immunotherapy and Biomarkers |
| related_works | https://openalex.org/W2515537233, https://openalex.org/W2708559543, https://openalex.org/W236807388, https://openalex.org/W2081815287, https://openalex.org/W2201793188, https://openalex.org/W2139614539, https://openalex.org/W3147275309, https://openalex.org/W2129685713, https://openalex.org/W3095184244, https://openalex.org/W2947088833 |
| cited_by_count | 10 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 3 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 5 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 2 |
| locations_count | 5 |
| best_oa_location.id | doi:10.1080/2162402x.2023.2192100 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2497914550 |
| best_oa_location.source.issn | 2162-4011, 2162-402X |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2162-4011 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | OncoImmunology |
| best_oa_location.source.host_organization | https://openalex.org/P4310315740 |
| best_oa_location.source.host_organization_name | Landes Bioscience |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310315740 |
| best_oa_location.license | cc-by-nc |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | OncoImmunology |
| best_oa_location.landing_page_url | https://doi.org/10.1080/2162402x.2023.2192100 |
| primary_location.id | doi:10.1080/2162402x.2023.2192100 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2497914550 |
| primary_location.source.issn | 2162-4011, 2162-402X |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2162-4011 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | OncoImmunology |
| primary_location.source.host_organization | https://openalex.org/P4310315740 |
| primary_location.source.host_organization_name | Landes Bioscience |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310315740 |
| primary_location.license | cc-by-nc |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | OncoImmunology |
| primary_location.landing_page_url | https://doi.org/10.1080/2162402x.2023.2192100 |
| publication_date | 2023-03-23 |
| publication_year | 2023 |
| referenced_works | https://openalex.org/W3128646645, https://openalex.org/W2781525129, https://openalex.org/W2098414192, https://openalex.org/W2138805058, https://openalex.org/W2042624738, https://openalex.org/W2299454500, https://openalex.org/W1994993231, https://openalex.org/W2065924876, https://openalex.org/W2755002661, https://openalex.org/W1979382909, https://openalex.org/W2158285723, https://openalex.org/W2981817124, https://openalex.org/W2913187956, https://openalex.org/W3034612062, https://openalex.org/W1493484733, https://openalex.org/W3139219057, https://openalex.org/W2619959350, https://openalex.org/W1480342889, https://openalex.org/W2909660453, https://openalex.org/W2059354338, https://openalex.org/W2278665679, https://openalex.org/W2948153999, https://openalex.org/W2288284945, https://openalex.org/W2140588588, https://openalex.org/W2811066004, https://openalex.org/W2965406966, https://openalex.org/W4239779200, https://openalex.org/W3049151577, https://openalex.org/W2419439766, https://openalex.org/W2418644771, https://openalex.org/W2806911036, https://openalex.org/W2128140185, https://openalex.org/W2121462928, https://openalex.org/W2751967109, https://openalex.org/W2081820230 |
| referenced_works_count | 35 |
| abstract_inverted_index.T | 187, 201 |
| abstract_inverted_index.a | 132, 219 |
| abstract_inverted_index.In | 33, 53 |
| abstract_inverted_index.NK | 103, 189 |
| abstract_inverted_index.an | 63, 194 |
| abstract_inverted_index.as | 70, 191, 193 |
| abstract_inverted_index.by | 102, 159 |
| abstract_inverted_index.in | 31, 74, 80, 90, 131, 144, 165, 170, 181, 196, 218, 243 |
| abstract_inverted_index.of | 4, 10, 38, 62, 93, 99, 109, 128, 152, 162, 185, 199, 208, 232 |
| abstract_inverted_index.on | 47, 213 |
| abstract_inverted_index.to | 21, 25, 141, 238 |
| abstract_inverted_index.The | 107, 149, 176, 205 |
| abstract_inverted_index.and | 58, 73, 78, 84, 96, 111, 136, 188, 235 |
| abstract_inverted_index.has | 44 |
| abstract_inverted_index.out | 17 |
| abstract_inverted_index.the | 1, 18, 27, 39, 56, 125, 153, 166, 197, 209, 230 |
| abstract_inverted_index.was | 68, 156, 215 |
| abstract_inverted_index.CD70 | 43 |
| abstract_inverted_index.CD8+ | 200 |
| abstract_inverted_index.Lung | 146 |
| abstract_inverted_index.been | 45 |
| abstract_inverted_index.both | 186 |
| abstract_inverted_index.cell | 117 |
| abstract_inverted_index.data | 228 |
| abstract_inverted_index.many | 48 |
| abstract_inverted_index.mice | 173 |
| abstract_inverted_index.need | 20 |
| abstract_inverted_index.over | 203 |
| abstract_inverted_index.that | 124 |
| abstract_inverted_index.this | 34, 54 |
| abstract_inverted_index.well | 192 |
| abstract_inverted_index.with | 76 |
| abstract_inverted_index.<i>in | 82, 85, 105, 120 |
| abstract_inverted_index.Lewis | 145 |
| abstract_inverted_index.NSCLC | 12, 81, 94, 116, 244 |
| abstract_inverted_index.These | 225 |
| abstract_inverted_index.aCD70 | 236 |
| abstract_inverted_index.after | 174 |
| abstract_inverted_index.agent | 72 |
| abstract_inverted_index.cells | 95, 104, 164, 202 |
| abstract_inverted_index.lymph | 168 |
| abstract_inverted_index.mice. | 148 |
| abstract_inverted_index.mouse | 223 |
| abstract_inverted_index.nodes | 169 |
| abstract_inverted_index.novel | 23, 226 |
| abstract_inverted_index.poor, | 15 |
| abstract_inverted_index.ratio | 198 |
| abstract_inverted_index.these | 171 |
| abstract_inverted_index.tumor | 138 |
| abstract_inverted_index.unmet | 19 |
| abstract_inverted_index.NSCLC. | 32, 52 |
| abstract_inverted_index.Tregs. | 204 |
| abstract_inverted_index.agents | 143 |
| abstract_inverted_index.cancer | 49 |
| abstract_inverted_index.cells, | 190 |
| abstract_inverted_index.effect | 207 |
| abstract_inverted_index.growth | 139 |
| abstract_inverted_index.immune | 5, 29, 40, 59, 241 |
| abstract_inverted_index.model. | 224 |
| abstract_inverted_index.recent | 2 |
| abstract_inverted_index.remain | 14 |
| abstract_inverted_index.showed | 123 |
| abstract_inverted_index.single | 71, 142 |
| abstract_inverted_index.study, | 55 |
| abstract_inverted_index.types, | 50 |
| abstract_inverted_index.(aCD70) | 66 |
| abstract_inverted_index.Despite | 0 |
| abstract_inverted_index.delayed | 137 |
| abstract_inverted_index.develop | 22 |
| abstract_inverted_index.enhance | 26, 239 |
| abstract_inverted_index.further | 114, 157, 216 |
| abstract_inverted_index.killing | 92 |
| abstract_inverted_index.numbers | 161 |
| abstract_inverted_index.regard, | 35 |
| abstract_inverted_index.regimen | 155 |
| abstract_inverted_index.therapy | 67, 88, 113, 179, 212, 237 |
| abstract_inverted_index.aberrant | 36 |
| abstract_inverted_index.clinical | 8 |
| abstract_inverted_index.compared | 140 |
| abstract_inverted_index.enhanced | 115, 182 |
| abstract_inverted_index.explored | 69 |
| abstract_inverted_index.findings | 122 |
| abstract_inverted_index.improved | 134 |
| abstract_inverted_index.increase | 195 |
| abstract_inverted_index.killing. | 118 |
| abstract_inverted_index.molecule | 42 |
| abstract_inverted_index.outcomes | 9 |
| abstract_inverted_index.patients | 13 |
| abstract_inverted_index.pointing | 16 |
| abstract_inverted_index.reported | 46 |
| abstract_inverted_index.response | 30 |
| abstract_inverted_index.resulted | 89, 130, 180 |
| abstract_inverted_index.superior | 206 |
| abstract_inverted_index.survival | 135, 214 |
| abstract_inverted_index.vivo</i> | 121 |
| abstract_inverted_index.Anti-CD70 | 87 |
| abstract_inverted_index.Moreover, | 119 |
| abstract_inverted_index.anti-CD70 | 65, 112 |
| abstract_inverted_index.cisplatin | 79 |
| abstract_inverted_index.combining | 233 |
| abstract_inverted_index.confirmed | 217 |
| abstract_inverted_index.cytokines | 101 |
| abstract_inverted_index.cytotoxic | 57 |
| abstract_inverted_index.dendritic | 163 |
| abstract_inverted_index.docetaxel | 77 |
| abstract_inverted_index.emergence | 3 |
| abstract_inverted_index.humanized | 221 |
| abstract_inverted_index.including | 51 |
| abstract_inverted_index.increased | 97, 160 |
| abstract_inverted_index.patients. | 245 |
| abstract_inverted_index.potential | 61, 151, 231 |
| abstract_inverted_index.responses | 242 |
| abstract_inverted_index.therapies | 24 |
| abstract_inverted_index.treatment | 127 |
| abstract_inverted_index.vitro</i> | 83 |
| abstract_inverted_index.vivo</i>. | 86 |
| abstract_inverted_index.anti-tumor | 28, 240 |
| abstract_inverted_index.checkpoint | 6, 41 |
| abstract_inverted_index.expression | 37 |
| abstract_inverted_index.metastatic | 11 |
| abstract_inverted_index.production | 98 |
| abstract_inverted_index.sequential | 126, 177, 210 |
| abstract_inverted_index.treatment. | 175 |
| abstract_inverted_index.vitro</i>. | 106 |
| abstract_inverted_index.NK-mediated | 91 |
| abstract_inverted_index.combination | 75, 108, 178, 211 |
| abstract_inverted_index.demonstrate | 229 |
| abstract_inverted_index.highlighted | 158 |
| abstract_inverted_index.immunogenic | 150 |
| abstract_inverted_index.inhibitors, | 7 |
| abstract_inverted_index.preclinical | 227 |
| abstract_inverted_index.significant | 133 |
| abstract_inverted_index.stimulatory | 60 |
| abstract_inverted_index.chemotherapy | 110, 234 |
| abstract_inverted_index.infiltration | 184 |
| abstract_inverted_index.intratumoral | 183 |
| abstract_inverted_index.tumor-bearing | 172 |
| abstract_inverted_index.IL15-NSG-CD34+ | 222 |
| abstract_inverted_index.antibody-based | 64 |
| abstract_inverted_index.tumor-draining | 167 |
| abstract_inverted_index.chemotherapeutic | 154 |
| abstract_inverted_index.pro-inflammatory | 100 |
| abstract_inverted_index.NCI-H1975-bearing | 220 |
| abstract_inverted_index.carcinoma-bearing | 147 |
| abstract_inverted_index.chemo-immunotherapy | 129 |
| cited_by_percentile_year.max | 98 |
| cited_by_percentile_year.min | 94 |
| corresponding_author_ids | https://openalex.org/A5079224330 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 12 |
| corresponding_institution_ids | https://openalex.org/I4210102047 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/1 |
| sustainable_development_goals[0].score | 0.4300000071525574 |
| sustainable_development_goals[0].display_name | No poverty |
| sustainable_development_goals[1].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[1].score | 0.4000000059604645 |
| sustainable_development_goals[1].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.90915789 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |